Millipore Corporation is pleased to announce the acquisition of key Alzheimer’s disease research products from The Genetics Company of Zurich, Switzerland. These products further support our extensive portfolio of Alzheimer’s disease reagents and represent Millipore’s continued commitment to excellence in neuroscience research. These key products include highly purified monoclonal antibodies and were developed in collaboration with leading Alzheimer’s disease researchers.
Highly selective, these antibodies specifically recognize beta-Amyloid peptides and are ideal for use in Western blotting, IH, ELISA and other applications, ensuring highly reproducible results.
Now Available
|
| MABN10 | Anti-human Amyloid β, clone WO-2 | 50 μg |
| MABN11 | Anti-human Amyloid β, clone G2-10 | 50 μg |
| MABN12 | Anti-human Amyloid β, clone G2-11 | 50 μg |
| MABN13 | Anti-human Amyloid β, clone G2-13 | 50 μg |
- Click here to view additional Amyoid beta antibodies
- Click here to view our complete list of Alzheimer’s related reagents
| |
For ordering information call 1-800-millipore or contact your local Millipore Account Manager.
